Amycretin
Also known as: Zenagamtide, NN9487, Unimolecular GLP-1/amylin agonist
Amycretin (also called Zenagamtide or NN9487) is an investigational GLP-1 + amylin unimolecular agonist. Amycretin is a single molecule that activates both the GLP-1 and amylin receptors, an approach sometimes described as unimolecular co-agonism — combining in one peptide the two satiety pathways that CagriSema addresses with two separate agents.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- FDA status
- Investigational New Drug (IND)
- Administration Route
- Oral or Subcutaneous
- Frequency
- Daily oral or weekly SC (formulation-dependent)
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- GLP-1 receptorAmylin receptor
Research summary
Novo Nordisk unimolecular GLP-1 and amylin receptor agonist in oral and subcutaneous forms, advancing to Phase 3. Not FDA-approved. Distinct from CagriSema.
Peptide Library's Amycretin profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Oral and SC titration in early-phase / Phase 3 programs
- Frequency
- Daily oral or weekly SC (formulation-dependent)
- Cycle
- —
- Administration Route
- Oral or Subcutaneous
- Reconstitution Guide
- —
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Amycretin is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Appearance | White lyophilized powder |
|---|---|
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Amycretin is a single molecule that activates both the GLP-1 and amylin receptors, an approach sometimes described as unimolecular co-agonism — combining in one peptide the two satiety pathways that CagriSema addresses with two separate agents. GLP-1 receptor activation contributes glucose-dependent insulin secretion, slowed gastric emptying and central appetite suppression, while amylin receptor activation acts principally through hindbrain nuclei to reduce meal size. Both subcutaneous and oral formulations have been studied in early-phase trials. It is investigational and not approved for any use.
Origin
Synthetic unimolecular dual agonist (Novo Nordisk).
Targets
Studies
- Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
- Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
- Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Regulatory & research status
Amycretin has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Clinical Trial |
Benefits
Potential Side Effects
Side Effects
- GI class effects
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Amycretin: frequently asked questions
What is Amycretin?
Novo Nordisk unimolecular GLP-1 and amylin receptor agonist in oral and subcutaneous forms, advancing to Phase 3. Not FDA-approved. Distinct from CagriSema.
How does Amycretin work?
Amycretin is a single molecule that activates both the GLP-1 and amylin receptors, an approach sometimes described as unimolecular co-agonism — combining in one peptide the two satiety pathways that CagriSema addresses with two separate agents. GLP-1 receptor activation contributes glucose-dependent insulin secretion, slowed gastric emptying and central appetite suppression, while amylin receptor activation acts principally through hindbrain nuclei to reduce meal size.
Is Amycretin FDA approved?
No. Amycretin is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.
Is Amycretin banned in sport?
Amycretin is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to Amycretin?
Compounds most often compared with Amycretin include Cagrilintide, Pramlintide, Petrelintide and CagriSema. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial — Lancet, 2026External reference
- Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial — Lancet, 2026External reference
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study — Lancet, 2025External reference
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial — Lancet, 2025External reference
- Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives — Metabolism, 2026External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Amycretin profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Amycretin research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →